Previous 10 | Next 10 |
2024-03-06 08:02:02 ET Aptevo Therapeutics Inc (APVO) announced stock split at a ratio of 1-for-44 on 2024-03-06 ... Full story available on KlickAnalytics.com
Announces 1H24 Plan for Development of Lead Candidate APVO436 for the Treatment of Frontline Acute Myeloid Leukemia, Interim Results Expected Late 2H24 ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues Enrollment, Interim Results Expected 1H24 SEATTLE, WA / A...
SEATTLE, WA / ACCESSWIRE / March 4, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) (" Aptevo " or the " Company "), today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-44 (the " Reverse Stock Split "). The Reverse Stock Split is...
2023-11-22 16:19:18 ET More on Aptevo Therapeutics Seeking Alpha’s Quant Rating on Aptevo Therapeutics Historical earnings data for Aptevo Therapeutics Financial information for Aptevo Therapeutics For further details see: Aptevo Therapeutics files...
2023-11-14 09:46:59 ET More on Aptevo Therapeutics Seeking Alpha’s Quant Rating on Aptevo Therapeutics Historical earnings data for Aptevo Therapeutics Financial information for Aptevo Therapeutics For further details see: Aptevo Therapeutics GAAP ...
The Company's ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues to Progress Planning for APVO436 Phase 2 Trial Initiation in Both Relapsed/Refractory and Frontline AML Ongoing Extended Cash Runway with $7 Million in Funding and Potential for Additional $9....
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Aptevo Therapeutics Inc. (APVO) is expected to report $-0.72 for Q3 2023
SEATTLE, WA / ACCESSWIRE / November 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the ...
2023-08-10 10:53:11 ET Aptevo Therapeutics press release ( NASDAQ: APVO ): Q2 GAAP EPS of -$1.23 misses by $0.11 . Aptevo had cash and cash equivalents as of June 30, 2023 totaling $21.0 million (exclusive of the proceeds from the equity raised closed on August 4, 2023...
News, Short Squeeze, Breakout and More Instantly...
Aptevo Therapeutics Inc. Company Name:
APVO Stock Symbol:
NASDAQ Market:
Aptevo Therapeutics Inc. Website:
Lecture to focus on engineering strategies applied to design safe and efficacious bispecific drug candidates, utilizing our proprietary platform technologies SEATTLE, WA / ACCESSWIRE / May 14, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on ...
Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after entering the ALG.APV-527 Phase 1 trial with progressive disease and transitioning to higher dose with potential for greater clinical benefit, experienced no new a...
A look at the top 10 most actives in the United States Allarity Therapeutics Inc. (ALLR) rose 97.8% to $2.71 on volume of 44,141,232 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 1.1% to $0.0456 on volume of 28,670,184 shares Emergent Biosolutions Inc. (EBS) rose 67.7% to $3...